TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.
TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.
TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.
TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.
The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.
TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.
The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.